Telix Reports 22% Revenue Growth as Radiopharma Portfolio Scales

Telix Pharmaceuticals' H1 2026 results signal that its dual-product commercial model is holding under operational pressure, with group revenue reaching US$477 million, a 22% year-over-year increase tracking toward the upper end of full-year guidance of US$950–970 million. For plant heads and supply chain leads, the more telling figure is the Precision Medicine gross margin of 65%, reflecting both favorable product mix and the operational efficiencies the company has been building into its radiopharmaceutical manufacturing infrastructure.

Illuccix® and Gozellix® drove a 27% year-over-year revenue increase in the Precision Medicine segment, with adjusted segment EBITDA rising 26% to US$132 million. That performance is not incidental to manufacturing discipline, radiopharmaceutical products carry short shelf lives and tight logistics windows, and sustaining volume growth at this scale requires validated supply chain processes and consistent site-level execution across distribution networks.

On the regulatory side, QA and regulatory affairs teams will note several concurrent review tracks. The FDA has assigned a PDUFA goal date of September 11, 2026 for Pixclara® (floretyrosine F 18) in glioma imaging, while the European MAA for Pixlumi® has been validated and accepted for review. For Zircaix® (zirconium-89 girentuximab senvedoxam), Telix received a corrected Complete Response Letter and an extended BLA resubmission deadline, with the company reporting active engagement with FDA to ensure the resubmission package addresses all outstanding CRL items, a process that typically demands rigorous CMC documentation and analytical method alignment.

The Regeneron collaboration, which contributed an initial non-refundable US$40 million payment and is focused on next-generation radiopharmaceutical therapies, adds a co-development dimension that will eventually require harmonized GMP frameworks between partners. Telix also completed a US$600 million convertible bond refinancing due 2031, extending the financial runway supporting its R&D spend of US$124 million in the first half, directed primarily at late-stage therapeutic and precision medicine programs.

Patient enrollment for the Phase 3 BiPASS™ study of Illuccix and Gozellix in the pre-biopsy prostate cancer imaging setting is nearing completion, and the Japan Phase 3 registrational study for Illuccix has reached enrollment completion, both milestones that move the company closer to additional regulatory submissions requiring validated manufacturing packages. An NDA for Illuccix is currently under review by China's NMPA Center for Drug Evaluation, adding a third major market to the regulatory workload.

The Zircaix BLA resubmission timeline will serve as a near-term indicator of how effectively Telix's regulatory and manufacturing teams have resolved the outstanding CRL items under an extended deadline.

Source: Telix Pharmaceuticals Limited via company press release, August 20, 2026.